eligibility_summary
Inclusion: adults ≥18 with advanced/metastatic solid tumor progressing after ≥2 prior approved lines (incl targeted), ECOG 0–1, measurable disease, adequate renal/hepatic/hematologic function, life expectancy ≥3 mo, able to comply. Exclusion: prior poxvirus oncolytic or CD19×CD3 engager, recent steroids/immunosuppression or radiation, autoimmune disease, severe skin wounds, ILD/pneumonitis, pancreatitis, allogeneic transplant, CNS mets only if treated/stable/off steroids ≥2 mo, major cardiac disease, bleeding diathesis/anticoagulation, significant CNS disorder, active infection.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1 OASIS tests: 1) CF33-CD19 (onCARlytics): a chimeric orthopox (vaccinia) oncolytic virus. Type: biological/viral therapy. Mechanism: selectively infects/replicates in and lyses tumor cells and is engineered to display truncated CD19 on infected tumor cells, “tagging” them as CD19+. 2) Blinatumomab: bispecific T‑cell engager (BiTE) antibody construct. Mechanism: binds CD3 on T cells and CD19 on target cells, activating T‑cell cytotoxicity against CF33‑CD19–tagged tumors. 3) Hydroxyurea: oral antimetabolite (ribonucleotide reductase inhibitor), adjunctive. Targets/pathways: tumor cells (oncolysis and forced CD19 expression), CD3+ T‑cell activation and synapse formation via blinatumomab, with broader modulation of the tumor immune microenvironment.